Novel precision medicine approaches such as Notable Labs’ ex vivo DSS identify rational drugs and drug combinations and predict clinical therapeutic responses
Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.
Notable has developed a versatile platform for testing a wide variety of drugs in patient ex vivo clinical samples, with a high-throughput flow cytometry readout that incorporates diverse phenotypes, including measures of apoptosis, proliferation, differentiation, and stemness, as well as immunotherapy targets.
Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.